Newsroom

  • Category

  • By Date

  • Press Release

    19 September 25

    CuraTeQ Biologics announces positive Phase 3 study results for Denosumab biosimilar

    Read more
  • Press Release

    04 July 25

    CuraTeQ Biologics receives EC marketing authorization for Dazublys – Trastuzumab biosimilar

    Read more
  • Press Release

    26 April 25

    CuraTeQ Biologics receives CHMP positive opinion for Dazublys – Trastuzumab biosimilar

    Read more